Table 2.
Changes in physicians' treatment recommendations pre- to post-Oncotype DX
| Patients | N | Overall change rate | CHT to HT, n (%) | HT to CHT, n (%) | Other, n (%) |
|---|---|---|---|---|---|
| All assessable | 366 | 121 (33%; 95% CI 28.3–38.1) | 79 (22) | 39 (11) | 3 (1) |
| Low RS | 198 | 72 (36%; 95% CI 29.7–43.5) | 68 (34) | 2 (1) | 2a,b(1) |
| Intermediate RS | 139 | 43 (31%; 95% CI 23.4–39.3) | 11 (8) | 31 (22) | 1c (1) |
| High RS | 29 | 6 (21%; 95% CI 8.0–39.7) | 0 (0) | 6 (21) | 0 (0) |
| Node negative | 244 | 74 (30%; 95% CI 24.6–36.5) | 45 (18) | 28 (12) | 1c (0) |
| Low RS | 131 | 39 (30%; 95% CI 22.1–38.4) | 38 (29) | 1 (1) | 0 (0) |
| Intermediate RS | 95 | 31 (33%; 95% CI 23.4–43.0) | 7 (7) | 23 (24) | 1c (1) |
| High RS | 18 | 4 (22%; 95% CI 6.4–47.6) | 0 (0) | 4 (22) | 0 (0) |
| Node positive | 122 | 47 (39%; 95% CI 29.9–47.8) | 34 (28) | 11 (9) | 2a,b (2) |
| Low RS | 67 | 33 (49%; 95% CI 36.8–61.8) | 30 (45) | 1 (2) | 2a,b (3) |
| Intermediate RS | 44 | 12 (27%; 95% CI 15.0–42.8) | 4 (9.1) | 8 (18) | 0 (0) |
| High RS | 11 | 2 (18%; 95% CI 2.3–51.8) | 0 (0) | 2 (18) | 0 (0) |
RS, Recurrence Score; CHT, chemoendocrine therapy; HT, endocrine therapy; CT, chemotherapy; 95% confidence intervals calculated using the Clopper–Pearson method.
aObservation to CHT.
bObservation to HT.
cCT to CHT.